Introduction {#s1}
============

In the USA, research is supervised by local institutional review boards (IRBs). Previously identified major obstacles to research that result from this regulatory structure include (1) a lack of consistent interpretation between IRBs of the types of risk in data collection; and (2) a lack of data to determine if consistency of process is being achieved at each site (ie, consistent need for full IRB review and/or need for consent).[@R1] Although the benefits of intense review might justify the barriers generated by local processes, it is less clear whether this is true for studies posing minimal risk to subjects.

Unfortunately, there is a paucity of literature on this topic. However, based on feedback received from primary investigators leading Eastern Association for the Surgery of Trauma (EAST) multicenter trials, as well as discussions of varying practices among committee members, we hypothesized that there is significant variation in perceptions of EAST members compared with IRB members regarding IRB requirements for review of observational trials, especially prospective observational trials without need for blood/tissue collection. Second, we hypothesized that there is significant variation in perceptions of need for informed consent between EAST members and IRB members. Third, we hypothesized that there would be significant variation within subgroups of EAST members based on research experience of the investigator (ie, \>2 previous IRB submissions vs. ≤2 IRB submissions) or institution (ie, level I American College of Surgeons (ACS) or state-verified center vs. non-level I ACS or state-verified center). Additionally, we sought to describe primary investigators' and IRB members' attitudes toward the need for review and consent in these types of studies.

Methods {#s2}
=======

The EAST Multicenter Trials (MCT) Committee conducted a study to evaluate the experiences of trauma researchers with their local IRB processes for studies posing minimal risk. At these same institutions, IRB members were asked to share their practices and their perceptions of the process. After obtaining IRB exemption at the University of California, Irvine, the EAST MCT Committee distributed an electronic survey to all currently active (licensed, board-certified surgeons, under the age of 50) and associate (physicians in non-surgical specialties and non-physicians) EAST members. The EAST MCT Committee members were also asked to provide a convenience sample of colleagues from their 14 affiliated institutions who were IRB members. This decision to use a convenience sample was due to the fact that there was no national organization or entity that could provide a list of similar institutions' IRB members. All IRB members came from an institution with at least one EAST member involved in the survey. The survey was distributed from June to October 2017 using a link to an anonymous REDCap survey.[@R5] Responses from EAST members who self-indicated that they had not been a primary investigator of an IRB-requiring project and from IRB members who self-indicated they were not currently part of an IRB were excluded from analysis. There were minor differences in the surveys administered to EAST versus IRB members (see online [supplementary appendix](#SP1){ref-type="supplementary-material"}).
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Descriptive statistics were performed for all data. Analyses were conducted comparing the responses from different groups of EAST members and also comparing those of EAST members with those of IRB personnel using the Fisher's exact test. All statistical analyses were performed with Stata V.14.2.

Results {#s3}
=======

From 1181 EAST members, 219 from the USA and Canada responded (18.5% overall response rate) to our online survey, with 160 meeting the inclusion criteria (13.5% response rate for those meeting the inclusion criteria) as a primary investigator of a current or previous project requiring IRB submission. These respondents declared their affiliation to be from 36 states. EAST members participated from 113 unique institutions, whereas IRB members participated from 14 institutions. From 14 different institutions, 45 potential IRB members were queried, and 29 responded (64.4% response rate), with 23 indicating they were currently an active IRB member. All IRB members who responded had corresponding EAST members from their home institution who also replied. EAST and IRB member demographic information is shown in [table 1](#T1){ref-type="table"}.

###### 

Group demographics of EAST and IRB members

  Survey                                        EAST         IRB
  --------------------------------------------- ------------ -----------
  IRB submissions in the past year              (n=158)      --
   1                                            18 (11.4)    --
   2                                            27 (17.1)    --
   3                                            41 (25.9)    --
   4                                            18 (11.4)    --
   5 or more                                    54 (34.2)    --
  Turnaround time (weeks) for IRB submissions   (n=155)      (n=22)
   \<1 week                                     5 (3.2)      3 (13.6)
   2--4 weeks                                   70 (45.2)    12 (54.5)
   4--8 weeks                                   59 (38.1)    6 (27.3)
   \>8 weeks                                    21 (13.5)    1 (4.5)
  Institution setting                           (n=159)      (n=21)
   University                                   121 (76.1)   20 (95.2)
   Private academic                             32 (20.1)    1 (4.8)
   Private non-academic                         6 (3.8)      0 (0)
  Trauma center verification (ACS or state)     (n=160)      --
   Level I                                      142 (88.8)   --
   Level II                                     15 (9.4)     --
   Level III                                    2 (1.3)      --
   Not verified                                 1 (0.6)      --

ACS, American College of Surgeons; EAST, Eastern Association for the Surgery of Trauma; IRB, institutional review board.

Retrospective observational studies {#s3a}
-----------------------------------

A full IRB review for retrospective studies using patient identifiers was reported to be required by 13.1% of EAST members, whereas 11.9% reported being assigned exemption from IRB review. In contrast, zero IRB member reported ever requiring a full IRB review or an exemption. Rather, the overwhelming majority reported a need for an expedited review (95.5%) (p=0.05) ([table 2](#T2){ref-type="table"}).

###### 

IRB review and informed consent for EAST and IRB members

  Survey                                                                                                    EAST         IRB         P values
  --------------------------------------------------------------------------------------------------------- ------------ ----------- ----------
  Level of IRB review required for retrospective observational trials using patient identifiers             (n=160)      (n=22)      0.05
   Exempt                                                                                                   19 (11.9)    0 (0)       
   Expedited review                                                                                         110 (68.8)   21 (95.5)   
   Full IRB review                                                                                          21 (13.1)    0 (0)       
   Case-by-case basis                                                                                       10 (6.3)     1 (4.5)     
  Level of informed consent required when using patient identifiers for retrospective studies               (n=160)      (n=22)      0.46
   Waiver of informed consent                                                                               121 (75.6)   19 (86.4)   
   Require informed consent                                                                                 13 (8.1)     0 (0)       
   Case-by-case basis                                                                                       26 (16.3)    3 (13.6)    
  Level of IRB review required for prospective observational trials WITHOUT blood/tissue collection         (n=160)      (n=21)      0.01
   Exempt                                                                                                   4 (2.5)      1 (4.8)     
   Expedited review                                                                                         60 (37.5)    12 (57.1)   
   Full IRB review                                                                                          77 (48.1)    2 (9.5)     
   Case-by-case basis                                                                                       19 (11.9)    6 (28.6)    
  Level of informed consent required for prospective observational trials WITHOUT blood/tissue collection   (n=159)      (n=22)      \<0.001
   Waiver of informed consent                                                                               49 (30.8)    1 (4.5)     
   Require informed consent                                                                                 58 (36.5)    2 (9.1)     
   Case-by-case basis                                                                                       52 (32.7)    19 (86.4)   
  Level of IRB review required for prospective observational trials WITH blood/tissue collection            (n=155)      (n=22)      \<0.001
   Exempt                                                                                                   1 (0.6)      0 (0)       
   Expedited review                                                                                         6 (3.9)      10 (45.5)   
   Full IRB review                                                                                          124 (80.0)   3 (13.6)    
   Case-by-case basis                                                                                       24 (15.5)    9 (40.9)    
  Level of informed consent required for prospective observational trials WITH blood/tissue collection      (n=156)      (n=22)      0.34
   Waiver of informed consent                                                                               3 (1.9)      0 (0)       
   Require informed consent                                                                                 118 (75.6)   14 (63.6)   
   Case-by-case basis                                                                                       35 (21.9)    8 (36.4)    
  Accepted policy/precedence available for prospective observational trials requiring informed consent      (n=150)      (n=21)      0.81
   No                                                                                                       65 (43.3)    10 (47.6)   
   Yes                                                                                                      85 (56.7)    11 (52.4)   

EAST, Eastern Association for the Surgery of Trauma; IRB, institutional review board.

Prospective observational studies {#s3b}
---------------------------------

Regarding prospective observational trials without blood/tissue collection, 48.1% of EAST members reported that their institutions required full IRB review and 36.5% required informed consent. The majority of IRB members (57.1%, p=0.01) reported their institutions allowed expedited review in these cases, with informed consent determined on a case-by-case basis (86.4%, p\<0.001). For prospective observational trials with blood/tissue collection, 80.0% of EAST members indicated a requirement to submit a full IRB review as compared with only 13.6% of IRB members (p\<0.001).

Informed consent, multicenter studies, and application fees {#s3c}
-----------------------------------------------------------

EAST and IRB members were queried on their opinions about the balance between subject protection and investigator research burden ([table 3](#T3){ref-type="table"}). Most EAST members (78.6%) stated that informed consent is not ethically necessary and thought that it was an unreasonable burden to research in prospective observational trials without blood/tissue collection. In contrast, most IRB members thought that informed consent was ethically necessary (63.6%, p\<0.001).

###### 

Informed consent and coordinating site for EAST and IRB members

  Survey                                                                                                                                                          EAST         IRB         P values
  --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ----------- ----------
  Do you feel informed consent for prospective observational trials WITHOUT blood/tissue collection is ethically necessary and a reasonable burden to research?   (n=159)      (n=22)      \<0.001
   No                                                                                                                                                             125 (78.6)   8 (36.4)    
   Yes                                                                                                                                                            34 (21.3)    14 (63.6)   
  Do you feel informed consent for prospective observational trials WITH blood/tissue collection is ethically necessary and a reasonable burden to research?      (n=158)      (n=22)      0.07
   No                                                                                                                                                             19 (12.0)    0 (0)       
   Yes                                                                                                                                                            139 (88.0)   22 (100)    
  Does your IRB currently accept IRB approval from an outside centralized institutional coordinating site to participate in multicenter studies/trials?           (n=157)      (n=22)      \<0.001
   No                                                                                                                                                             99 (62.7)    0 (0)       
   Yes                                                                                                                                                            59 (37.3)    22 (100)    
  Does your IRB currently allow your institution to serve as a coordinating site IRB holder for multicenter studies/trials?                                       (n=157)      (n=22)      0.41
   No                                                                                                                                                             36 (22.9)    3 (13.6)    
   Yes                                                                                                                                                            121 (77.1)   19 (86.4)   

EAST, Eastern Association for the Surgery of Trauma; IRB, institutional review board.

With regard to multicenter trials, 62.7% of EAST members reported that their home institution does not allow IRB approval from an outside centralized institution coordinating site to participate in multicenter studies/trials. In contrast all IRB members indicated their home institutions allow this (p\<0.001).

A fee for non-industry retrospective study applications was required in 13.2% of EAST members' responses (fee ranged from \$95 to \$3500), but in none of the IRB members' responses (see online [supplementary appendix table 1](#SP1){ref-type="supplementary-material"}).

Subgroup analyses {#s3d}
-----------------

On subgroup analysis comparing the responses of EAST members from a level I state or ACS-verified trauma center with those of a non-level I center, there were no significant differences in any of the questions (see online [supplementary appendix tables 2--4](#SP1){ref-type="supplementary-material"}).

We then compared EAST members involved in ≤2 IRB-required projects with those who had completed ≥3 IRB-required projects. More EAST members with less than two IRB-required projects reported the requirement of a full IRB review for retrospective studies compared with those EAST members involved with three or more IRB-required projects (26.7% vs. 7.1%, p=0.01). Conversely, EAST members with ≤2 IRB-required projects reported a lower rate for waiver of informed consent (66.7% vs. 79.7%, p=0.03) ([table 4](#T4){ref-type="table"}). There were no significant differences for the other questions (see online [supplementary appendix tables 5--6](#SP1){ref-type="supplementary-material"}).

###### 

IRB review and informed consent for EAST members with ≤2 IRBs compared with those with \>2

  Survey                                                                                                    ≤2 IRBs     \>2 IRBs    P values
  --------------------------------------------------------------------------------------------------------- ----------- ----------- ----------
  Level of IRB review required for retrospective observational trials using patient identifiers             (n=45)      (n=112)     0.01
   Exempt                                                                                                   3 (6.7)     16 (14.2)   
   Expedited review                                                                                         26 (57.8)   83 (73.5)   
   Full IRB review                                                                                          12 (26.7)   8 (7.1)     
   Case-by-case basis                                                                                       4 (8.9)     6 (5.3)     
  Level of informed consent required when using patient identifiers                                         (n=45)      (n=113)     0.03
   Waiver of informed consent                                                                               30 (66.7)   90 (79.7)   
   Require informed consent                                                                                 8 (17.8)    5 (4.4)     
   Case-by-case basis                                                                                       7 (15.6)    18 (15.9)   
  Level of IRB review required for prospective observational trials WITHOUT blood/tissue collection         (n=45)      (n=113)     0.80
   Exempt                                                                                                   1 (2.2)     3 (2.7)     
   Expedited review                                                                                         15 (33.3)   45 (39.8)   
   Full IRB review                                                                                          22 (48.9)   53 (46.9)   
   Case-by-case basis                                                                                       7 (15.6)    12 (10.6)   
  Level of informed consent required for prospective observational trials WITHOUT blood/tissue collection   (n=44)      (n=113)     0.57
   Waiver of informed consent                                                                               11 (25.0)   38 (33.6)   
   Require informed consent                                                                                 18 (40.9)   39 (34.5)   
   Case-by-case basis                                                                                       15 (34.1)   36 (31.9)   
  Level of IRB review required for prospective observational trials WITH blood/tissue collection            (n=44)      (n=109)     0.08
   Exempt                                                                                                   0 (0.0)     1 (0.9)     
   Expedited review                                                                                         0 (0.0)     6 (5.5)     
   Full IRB review                                                                                          33 (75.0)   89 (81.7)   
   Case-by-case basis                                                                                       11 (25.0)   13 (11.9)   
  Level of informed consent required for prospective observational trials WITH blood/tissue collection      (n=44)      (n=110)     0.93
   Waiver of informed consent                                                                               1 (2.3)     2 (1.8)     
   Require informed consent                                                                                 34 (77.3)   83 (75.5)   
   Case-by-case basis                                                                                       9 (20.5)    25 (22.7)   
  Accepted policy/precedence available for prospective observational trials requiring informed consent      (n=43)      (n=105)     0.08
   No                                                                                                       23 (53.5)   41 (39.0)   
   Yes                                                                                                      20 (46.5)   64 (61.0)   

EAST, Eastern Association for the Surgery of Trauma; IRB, institutional review board.

Finally, we compared EAST members from private institutions with those from a university setting. There were no significant differences (see online [supplementary appendix tables 7--8](#SP1){ref-type="supplementary-material"}), except that a lower rate of EAST members from a university setting thought that informed consent for prospective studies with blood/tissue collection is ethically necessary and a reasonable burden to research (84.9% vs. 97.4%, p=0.03) ([table 5](#T5){ref-type="table"}).

###### 

Informed consent and coordinating site for EAST members from private compared with university setting

  Survey                                                                                                                                                          Private     University   P values
  --------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ------------ ----------
  Do you feel informed consent for prospective observational trials WITHOUT blood/tissue collection is ethically necessary and a reasonable burden to research?   (n=38)      (n=120)      0.57
   No                                                                                                                                                             30 (79.0)   94 (78.3)    
   Yes                                                                                                                                                            8 (21.0)    26 (21.7)    
  Do you feel informed consent for prospective observational trials WITH blood/tissue collection is ethically necessary and a reasonable burden to research?      (n=38)      (n=119)      0.03
   No                                                                                                                                                             1 (2.6)     18 (15.1)    
   Yes                                                                                                                                                            37 (97.4)   101 (84.9)   
  Does your IRB currently accept IRB approval from an outside centralized institutional coordinating site to participate in multicenter studies/trials?           (n=37)      (n=120)      0.44
   No                                                                                                                                                             21 (56.8)   77 (64.2)    
   Yes                                                                                                                                                            16 (43.2)   43 (35.8)    
  Does your IRB currently allow your institution to serve as a coordinating site IRB holder for multicenter studies/trials?                                       (n=37)      (n=119)      0.02
   No                                                                                                                                                             14 (37.8)   22 (18.5)    
   Yes                                                                                                                                                            23 (62.2)   97 (81.5)    

EAST, Eastern Association for the Surgery of Trauma; IRB, institutional review board.

Discussion {#s4}
==========

Our study demonstrates significant discrepancies between EAST and IRB members' perceptions of local review and consent practices. Over 95% of the IRB members reported that retrospective studies met the criteria for expedited review, whereas only about two-thirds of EAST members understood this to be the case at their institution. Over 13% of EAST members stated these studies required full IRB review, whereas no IRB member reported a retrospective study with patient identifiers required full IRB review. Until recently, the Office for Human Research Protections' expedited review was intended for research activities that present no more than minimal risk to human subjects and meet one of nine categories of research.[@R6] However, beginning January 2018 the Common Rule included new categories of exemption, including secondary research involving identifiable private information if the research is regulated by and participants protected under the Health Insurance Portability and Accountability Act rules.[@R7] Clearly, greater investigator education is needed focusing on which studies qualify for expedited review.

Perceptions of review and consent requirements for prospective observational research studies without blood/tissue sampling demonstrated significant variation between IRB and EAST members but also among the members of each group. Both EAST and IRB members had answers ranging from IRB exemption to full IRB review, with neither group having a single answer that achieved 50% majority. Furthermore, over 86% of IRB members' responses indicated that requirement of informed consent for study participants in prospective observational research without blood/tissue sampling was decided on a case-by-case basis. Polito *et al* [@R8] highlighted this issue in a survey of 36 primary investigators at four centers, citing IRB concerns about waiver of consent as a major barrier to approval of a multicenter observational critical care study.

Multiple publications have similarly concluded that there is significant variation to the IRB process and approval in multicenter observational studies that pose minimal risk of harm.[@R9] A proposed solution to this issue is the use of a single centralized IRB. Although 100% of IRB members in our study reported allowing the use of outside central IRBs, this approach has notable disadvantages, including the lack of a local brick-and-mortar structure and IRB relationship with the communities it serves.[@R11] The role of centralized IRBs will increase with the implementation of the new Common Rule in January 2018. Under this revised rule, single-IRB review for multi-institutional studies will become the default; however, due to some concerns, the rule provides provisions allowing any federal agency supporting or conducting research to be permitted to determine if a single IRB is not appropriate for a particular context and therefore review should be done at each center's IRB.[@R7] Despite these efforts, there is no doubt that for single-center studies, efforts must be made to increase consistency of which prospective observational studies require or do not require informed consent. This is especially pertinent for trauma research, where the burden of consent of many subjects coupled with the emergent nature of injuries may inhibit investigation regarding emergent conditions.

For prospective observational studies, 56.7% of EAST members and 52.4% of IRB members replied there is a precedent or policy for consent determination. Additionally, our study demonstrated that 21.3% of EAST members thought it a reasonable research burden or ethically necessary or both to require informed consent as compared with almost two-thirds of IRB members. A previous study at a level I trauma center reported that 43% of trauma patients appeared incapable of consent, with 20% being 'unconsentable' even with use of a legally authorized representative.[@R13] Our survey included a space for free-text responses. A common theme reported was that investigators appeared to avoid prospective observational studies if they were from centers that required informed consent to conduct such studies. Fox *et al* [@R14] studied the waiver of consent in non-interventional research based on the Prospective Observational Multi-center Major Trauma Transfusion study. They found that if one of the sites' IRB had required withdrawal of patients unable to consent, this would have introduced significant bias to their data. They recommended that more observational studies should publish details about consent to gain more information about refusal rates and how these might affect non-interventional study results and quality.

Our study is small and based on survey opinions and as such has many limitations. The data collected from a small cohort of EAST and IRB members represent perceptions, not necessarily norms, regulations or even actual occurrences within each respondent's institution. Also, 90% of centers with respondents had only one or two respondents, making any intrainstitutional analysis unfeasible. Responder bias is also a significant limitation given the 13.5% EAST member response rate. Although we cannot completely assuage concerns about selection bias, we think the results are generalizable especially given the variation in answers between IRB members, who should in a manner act as a control for the knowledge of actual procedures within an institution. Of note, all of these IRB members resided at an institution where there were concurrent EAST members. That said, there is a clear limitation to the use of a small (14 centers) convenience sample size of IRB members. Unfortunately, there is no national registry or database of IRB members to query, and it was thought that an unsolicited email survey regarding an institution's IRB processes would achieve an unacceptably low response rate.

Despite these limitations, the authors involved in this study think the study clearly demonstrates that there is significant variation regarding the need for informed consent. Although any final decision regarding this topic would require a multidisciplinary consensus statement involving researchers, ethicists, national research organizations and members from IRBs, we do think that prospective observational research that does not require blood/tissue utilization clearly falls within a category of minimal risk/harm and should not require informed consent. We aspire that this article will serve as an impetus to create a national multidisciplinary coalition that can attempt to solve this issue that affects multicenter research throughout the nation.

Conclusion {#s5}
==========

There appears to be significant variation in perception and practice regarding prospective observational studies for IRB review process and whether informed consent is necessary. Review requirements for these observational studies ranged from exempt to full IRB review as described by both EAST and IRB members. Over two-thirds of IRB and EAST members reported that the need for consent for prospective observational studies was determined either on a case-by-case basis or required full review. Future discussion and research with respect to trauma investigations using an observational approach are needed to better determine the benefits of consent balanced with potential bias of study results. Additionally, there was significant variation between EAST and IRB members regarding IRB exemption criteria. We recommend that future interdisciplinary efforts between researchers and IRBs occur to better standardize local IRB efforts across the country.
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